Bonnie W Ramsey

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report
    Bonnie W Ramsey
    Seattle Children s Research Institute, WA, USA
    Am J Respir Crit Care Med 185:887-92. 2012
  2. ncbi Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
    Bonnie W Ramsey
    Department of Pediatrics, University of Washington, Seattle, WA 98105 0371, USA
    Proc Am Thorac Soc 4:367-9. 2007
  3. ncbi Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis
    Bonnie W Ramsey
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Proc Am Thorac Soc 4:359-63. 2007
  4. ncbi Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report
    Bonnie W Ramsey
    University of Washington School of Medicine, Seattle, Washington, USA
    J Pediatr 149:S15-9. 2006
  5. ncbi A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
    Bonnie W Ramsey
    Seattle Children s Hospital and University of Washington School of Medicine, Seattle WA 98105 0371, USA
    N Engl J Med 365:1663-72. 2011
  6. ncbi Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
  7. ncbi Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
  8. ncbi Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression
    Lucas R Hoffman
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Cyst Fibros 8:66-70. 2009
  9. ncbi Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
  10. ncbi Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012

Research Grants

  1. INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS
    Bonnie Ramsey; Fiscal Year: 2003

Detail Information

Publications27

  1. ncbi Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report
    Bonnie W Ramsey
    Seattle Children s Research Institute, WA, USA
    Am J Respir Crit Care Med 185:887-92. 2012
    ....
  2. ncbi Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?
    Bonnie W Ramsey
    Department of Pediatrics, University of Washington, Seattle, WA 98105 0371, USA
    Proc Am Thorac Soc 4:367-9. 2007
  3. ncbi Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis
    Bonnie W Ramsey
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Proc Am Thorac Soc 4:359-63. 2007
    ..In addition, there is a need for additional longitudinal epidemiology studies to establish the association of CT changes with other outcome measures, such as pulmonary function tests, quality of life measures, and mortality...
  4. ncbi Appropriate compensation of pediatric research participants: thoughts from an Institute of Medicine committee report
    Bonnie W Ramsey
    University of Washington School of Medicine, Seattle, Washington, USA
    J Pediatr 149:S15-9. 2006
  5. ncbi A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
    Bonnie W Ramsey
    Seattle Children s Hospital and University of Washington School of Medicine, Seattle WA 98105 0371, USA
    N Engl J Med 365:1663-72. 2011
    ..Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis...
  6. ncbi Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
    ..To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF)...
  7. ncbi Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
    ..Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood...
  8. ncbi Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression
    Lucas R Hoffman
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Cyst Fibros 8:66-70. 2009
    ..Pseudomonas aeruginosa with mutations in the transcriptional regulator LasR chronically infect the airways of people with cystic fibrosis (CF), yet the prevalence and clinical implications of lasR mutant infection are unknown...
  9. ncbi Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
    ..The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown...
  10. ncbi Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
    ..We aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations...
  11. ncbi Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
    Pediatr Pulmonol 42:610-23. 2007
    ..Early intervention strategies include tobramycin solution for inhalation (TSI), which can eradicate lower airway Pa from cultures obtained at the end of 28 days of treatment in young children...
  12. ncbi Association between pulmonary function and sputum biomarkers in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, 4800 Sand Point Way N E, Box 5371, Seattle, WA 98105 0371, USA
    Am J Respir Crit Care Med 175:822-8. 2007
    ..Validation of these biomarkers as correlates of disease severity is a key step for their application...
  13. ncbi Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients
    David A D'Argenio
    Department of Microbiology, University of Washington, Seattle, WA, USA
    Mol Microbiol 64:512-33. 2007
    ..Loss of LasR function may represent a marker of an early stage in chronic infection of the CF airway with clinical implications for antibiotic resistance and disease progression...
  14. ncbi Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
    Eric E Smith
    Genome Center, Program in Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:8487-92. 2006
    ..aeruginosa strains present in advanced CF infections differ systematically from those of "wild-type" P. aeruginosa and that these differences may offer new opportunities for treatment of this chronic disease...
  15. ncbi Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials
    Heidi Sucharew
    CF Therapeutics Development Network Coordinating Center, Seattle, WA, United States
    Contemp Clin Trials 27:561-70. 2006
    ..The tables published from this study can be used to assist those charged with safety monitoring in CF clinical trials...
  16. ncbi Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:19890-5. 2006
    ....
  17. ncbi Pathophysiology and management of pulmonary infections in cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington School of Medicine, Children s Hospital, Seattle, WA 98125, USA
    Am J Respir Crit Care Med 168:918-51. 2003
    ..In addition, the article discusses infection control policies, therapies to optimize airway clearance and reduce inflammation, and potential future therapies...
  18. ncbi Cystic fibrosis therapeutics: the road ahead
    Lucas R Hoffman
    Seattle Children s Hospital, Seattle, WA 98105, USA
    Chest 143:207-13. 2013
    ....
  19. ncbi Laboratory parameter profiles among patients with cystic fibrosis
    Christopher H Goss
    Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    J Cyst Fibros 6:117-23. 2007
    ..Laboratory-specific normal reference ranges may not accurately reflect what is abnormal but clinically insignificant among CF patients...
  20. ncbi Advancing outcome measures for the new era of drug development in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, WA 98105 0371, USA
    Proc Am Thorac Soc 4:370-7. 2007
    ..A systematic, rigorous approach to outcome measure development is needed to provide the tools necessary for evaluating new therapies and moving drugs out of the pipeline and into the CF clinic...
  21. ncbi Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, WA 98101 9300, USA
    Contemp Clin Trials 34:232-8. 2013
    ..The objectives of this study were to characterize emergence rates of elevated LFTs in CF trials and their association with clinical outcomes...
  22. ncbi Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis
    Robert K Ernst
    Department of Microbiology, University of Washington, Health Sciences Building, K 140, Box 357710, Seattle, WA 98195, USA
    Environ Microbiol 5:1341-9. 2003
    ..Further characterization of P. aeruginosa diversity within the airways of individual CF patients may reveal common adaptations, perhaps mediated by gene loss, that suggest new opportunities for therapy...
  23. ncbi Clinical trial participants compared with nonparticipants in cystic fibrosis
    Christopher H Goss
    University of Washington Medical Center, Campus Box 356522, 1959 N E Pacific, Seattle, WA 98195, USA
    Am J Respir Crit Care Med 173:98-104. 2006
    ..The randomized clinical trial has been an important tool for expanding our knowledge of disease. This study is the first to compare trial participants to the entire eligible population...
  24. ncbi Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington, Seattle, USA
    Curr Opin Pulm Med 9:492-7. 2003
    ..There is a critical need for further investigation of the clinical outcomes associated with early intervention, the long-term safety profile, and the optimal drug regimen...
  25. ncbi To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa?
    Bonnie W Ramsey
    Am J Respir Crit Care Med 166:906-7. 2002
  26. ncbi Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
    Chest 122:219-26. 2002
    ....
  27. ncbi Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis
    Robin R Deterding
    The Children s Hospital, 1056 East 19th Avenue, B395, Denver, CO 80218, USA
    Am J Respir Crit Care Med 176:362-9. 2007
    ....

Research Grants3

  1. INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS
    Bonnie Ramsey; Fiscal Year: 2003
    ..abstract_text> ..